Joey Moore
Member
Market Overview
The Europe biopsy devices market was valued at USD 629.6 Million in 2024 and is projected to reach USD 1,044.27 Million by 2033. It is expected to grow at a CAGR of 5.78% during the forecast period of 2025-2033. Market growth is driven by demand for advanced, cost-effective, minimally invasive procedures and technological advancements enhancing diagnostic precision and operational efficiency.
Study Assumption Years
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
- Current Market Size: USD 629.6 Million in 2024
- CAGR: 5.78% (2025-2033)
- Forecast Period: 2025-2033
- The rising prevalence of breast, lung, and prostate cancers is a significant growth driver.
- Needle biopsy segment dominates due to minimal invasiveness and high diagnostic accuracy.
- Technological innovations like AI-enabled imaging and robotic biopsy systems are improving procedure effectiveness.
- The United Kingdom leads the regional market due to strong healthcare infrastructure and early cancer diagnosis focus.
- Hospitals and clinics are the leading end users because of their advanced medical infrastructure and high patient volumes.
Market Growth Factors
Factors such as the demand for advanced, cost-effective, and customized biopsy devices that improve workflow efficiency and the rising demand for minimally intrusive needle, image-guided, and robotic diagnosis biopsies that provide rapid and accurate are driving the growth of the European biopsy devices market. In addition, the increasing emphasis on early cancer detection and prevention healthcare is driving the growth of the biopsy devices market in Europe.
Automation, artificial intelligence (AI) and improved imaging techniques such as ultrasound-guided and MRI-guided biopsy are improving the speed, quality and accuracy of tissue procurement, making the procedure faster and improving patient care. In 2024, Hologic's Brevera Breast Biopsy System was improved with 7-gauge needle technology to improve the quality and efficiency of procuring tissue samples and observed greater patient comfort.
Governmental initiatives, such as the European Commission's Beating Cancer Plan at a cost of 020 4 billion, and cancer screenings lead to an increased number of early-stage cancer diagnoses and cancer biopsies. Advanced diagnostic imaging in developed European countries allows hospitals and diagnostic centers to apply advanced biopsy devices for medical diagnostics. Trends for personalized medicine fuel molecular profiling and liquid biopsy technologies.
Market Segmentation
Procedure Type:
- Surgical Biology
- Needle Biopsy
Product:
- Biopsy Guidance Systems
- Needle Based Biopsy Guns
- Biopsy Needles
- Biopsy Forceps
- Others
Application:
- Breast Biopsy
- Lung Biopsy
- Colorectal Biopsy
- Prostate Biopsy
- Others
Guidance Technique:
- Ultrasound-guided Biopsy
- Stereotactic-guided Biopsy
- MRI-guided Biopsy
- Others
End User:
- Hospitals and Clinics
- Academic and Research Institutes
- Others
Country:
- Germany
- France
- United Kingdom
- Italy
- Spain
- Others
The United Kingdom is the dominant region within the Europe biopsy devices market, attributed to its robust healthcare infrastructure and strong emphasis on early cancer diagnosis and treatment. The UK's comprehensive network of diagnostic facilities equipped with advanced biopsy technologies ensures high accessibility and operational efficiency. Additionally, ongoing collaborations and awareness campaigns by organizations like the NHS boost market growth in this region.
Recent Developments & News
- In October 2024, University College Cork and Health Innovation Hub Ireland launched CLISTEPROBE, a technology using real-time bioimpedance sensors for rapid breast cancer biopsy result differentiation, aimed at reducing unnecessary procedures and speeding diagnosis.
- In January 2024, Clatterbridge Cancer Center implemented a digital plan to enhance patient care and research, including testing OnControl powered biopsy device which shortens bone marrow biopsy duration and minimizes patient discomfort.
- In 2024, SYNDEO Medical received European Medical Device Regulation (MDR) approval for their biopsy instrument procedure packs enhancing interventional and surgical procedures.
- SOPHiA GENETICS partnered with AstraZeneca in 2024 to deploy MSK-ACCESS® liquid biopsy testing at 20 institutions globally, including those in the UK, complementing traditional biopsy methods for improved cancer diagnosis and monitoring.
- Prothea Technologies secured 012 million funding in 2024 to develop combined biopsy and therapy solutions using fiber-optic and laser-ablation technology.
- Hologic, Inc.
- SYNDEO Medical
- SOPHiA GENETICS
- AstraZeneca
- Prothea Technologies
About Us
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, considerations studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.